Nautilus Biotechnology, Inc. — Form SCHEDULE 13D/A
Filed September 11, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 18/100
What the filing says
AH Bio Fund II, L.P. (filer address: Menlo Park, CA) filed an amended Schedule 13D/A on September 11, 2026 regarding beneficial ownership in Nautilus Biotechnology, Inc. (Seattle, WA). The filing document does not contain specific share count, percentage ownership, or transaction details in the provided text — only the amendment notice and filer/subject company identities are present.
Why this rating
Amendment filing lacks substantive disclosure of ownership changes, share counts, or valuations. Without specifics, impossible to assess materiality. Routine amendment document.
See more from September 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.